ArticleHepatology forum2026
The usefulness of a simultaneous immunoassay for hepatitis C virus antigen-antibody using the ELECSYS HCV Duo assay.
Article in Hepatology forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: The World Health Organization has a goal to eliminate the hepatitis C virus (HCV) by 2030. To achieve this, effective screening for HCV is essential. We evaluated the utility of the ELECSYS® HCV Duo immunoassay (Duo assay) for HCV screening. Materials and Methods: This single-center retrospective study included 184 HCV patients from 2014 to 2017. We measured HCV antibody (Duo/Ab) and HCV core antigen (Duo/cAg) using the Duo assay in HCV RNA-positive samples obtained before DAA therapy. We compared Duo/cAg positivity rates according to host and viral factors. We also performed logistic regression analysis and decision tree analysis to identify independent factors and profiles for Duo/cAg false-negative results, respectively. Results: Duo/Ab positivity rates were 100%, and Duo/cAg positivity rates were 78% in all subjects. Duo/cAg positivity rates were 40.0%, 78.6%, and 92.9% at HCV RNA levels ≤4.9, 5.0-5.9, and ≥6.0 log IU/mL, respectively (p<0.0001). There were no significant differences in Duo/cAg positivity rates by gender, age, body mass index, ALT >30 U/L, and HCV genotype. In multivariate analysis, the HCV RNA level (Unit -1.0 log IU/mL, OR 5.49, CI 3.12-10.56, p<0.0001) was the only independent factor associated with Duo/cAg false-negative results. Decision tree analysis revealed that HCV RNA ≥5.7 log IU/mL was the profile associated with the lowest false-negative rate (7.4%). In contrast, HCV RNA <4.4 log IU/mL was the profile associated with the highest false-negative rate (100%). Conclusion: The Duo assay identified approximately 80% of HCV carriers without HCV RNA measurement, regardless of patient background, providing substantial clinical, economic, and time-saving benefits. However, clinicians should be aware of limitations in patients with low HCV RNA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.